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Abstract
Background: The present study was intended to explore whether three proteins within MAPK signaling pathway (i.e.
p38MAPK-1, HIF-1 and HO-1) were correlated with peri-menopausal women’s coronary lesion features and prognosis.
Methods: Altogether 1449 peri-menopausal women were divided into non-coronary artery disease (CAD) group (n= 860)
and CAD group (n= 589), including 167 pre-menopausal CAD populations and 422 post-menopausal CAD populations.
General information about CAD risk parameters were gathered, including age, family history of CAD or
hypertension or diabetes mellitus, bilirubin, cholesterol, triglyceride, high-density lipoprotein cholesterol (HDL-C) and
low-density lipoprotein cholesterol (LDL-C) and so on. Coronary angiography results were judged, and CAD score was
calculated with application of Genisin scoring method. Besides, detection of MAPK-1 levels was implemented with
Strept Avidin-Biotin Complex (SABC) method, while HIF-1 and HO-1 expressions in the serum were determined utilizing
ELISA detection kit. Correlations among protein expressions, characteristics of coronary lesions and prognosis of CAD
populations were finally evaluated.
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Results: Hypertension, hyperlipoidemia, diabetes and smoking history were more prevalent among postmenopausal
CAD women than premenopausal CAD women (P < 0.05). Furthermore, postmenopausal women seemed to be
significantly associated with multiple (i.e. double and triple) vessel lesions and severe lesion types (type B and C), when
compared with premenopausal CAD group (P < 0.05). Similarly, remarkably elevated expressions of p38MAPK-1, HIF-1
and HO-1 were found within postmenopausal CAD populations in comparison to premenopausal ones (P < 0.05). The
internal CysC, hs-CRP, TG and LDL-C concentrations all accorded with the following tendency: postmenopausal CAD
women > premenopausal CAD women > non-CAD women. Moreover, p38MAPK-1, HIF-1 and HO-1 expressions were
up-regulated with increasing number of vessel lesions and severity of coronary lesions among peri-menopausal
women. Besides, among both pre-menopausal and post-menopausal CAD groups, positive correlations could be
observed between MAPK-1 and TG (rs = 0.271; rs = 0.476), between HIF-1α and LDL-C (rs = 0.077; rs = 0.470), as well as
between HO-1 and CysC (rs = 0.492; rs = 0.190) or hs-CRP (rs = 0.569; rs = 0.542) (all P < 0.05). MAPK-1, HIF-1α and HO-1
were also, respectively, positively correlated with CysC (rs = 0.415), hs-CRP (rs = 0.137), and TG (rs = 0.142), regarding
post-menopausal CAD women (all P < 0.05). Finally, only SBP and TG were regarded as independent risk factors for
CAD prognosis (i.e. high Genisin score) among premenopausal women (OR = 1.02, 95%CI: 1.01–1.18, P = 0.043;
OR = 1.82, 95%CI: 1.01–3.33, P = 0.047).
Conclusions: Expressions of p38MAPK-1, HIF-1 and HO-1 could serve as predictive roles for coronary lesions
among peri-menopausal women.
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Background
Cardiovascular disorders, especially coronary artery
disease (CAD), always stand high in their causal mortal-
ity and morbidity [1]. It has been stressed that CAD was
more prevalently found in men than in women for that
estrogen can, to some extent, safeguard women from
risk of CAD [2]. Nonetheless, emerging documentaries
suggested that women who were below 50 years old
appeared to be associated with 2 folds of mortality rate
when compared with men of matched ages [3]. The
potential account for this distinct contrast could be
hypothesized as hypoestrogenaemia, apart from certain
well-established classical risk elements, including smok-
ing history, hypertension, hyperlipidemia, diabetes and
so on [4]. Epidemiological data has also confirmed a
remarkable rise of CAD prevalence among postmeno-
pausal populations, despite a lower susceptibility to
CAD among premenopausal women than that within
men [5]. However, due to the under-estimation of CAD
among women, systematic evaluations targeting peri-
menopausal women and relevant underlying mecha-
nisms still remained lacking [6].
Diverse proteins have been speculated as reliable
serum biomarkers for susceptibility to CAD, such as adi-
pocyte fatty acid-binding protein (A-FABP), retinol-
binding protein-4 (RBP4), hypoxia inducible factor-1
(HIF-1), heme oxygenase-1 (HO-1) and so on [7–10].
Notably, HIF-1 was subject to regulation of estrogen via
correlated Akt and p38-mitogen activated protein kinase
(p38MAPK) pathways, implying that HIF-1 might
emerge as the featured biomarker between premenopausal
and postmenopausal populations [11]. In addition, since
HIF-1/HO-1 signaling pathway was involved with the
molecular mechanism that contributed to development of
myocardial ischemia, HO-1 was also incorporated as
a candidate protein that could be modified by estro-
gen [12, 13]. Besides, p38MAPK appeared to be
commonly investigated in the area of myocardial inflam-
mation, rather than CAD, yet it functioned as the
upstream molecule of HIF-1 [14]. As myocardial inflam-
mation was highly correlated with CAD [15], p38MAPK
could also count much in differentiating CAD from non-
CAD, even in marking the discrepancies between premen-
opausal and postmenopausal CAD.
Above all, multiple factors related with CAD for
women were distinct from that for men, regardless of
clinical manifestations, pathogenesis, diagnosis, drug
metabolism and prevention strategies. The present study
was intended to explore characteristic proteins that
could be tightly linked with perimenopausal CAD risk
and coronary artery lesions, providing solid evidence for
further exploration of treatment targets for CAD.
Methods
Subjects
Altogether 1449 peri-menopausal women suspected with
CAD were checked with coronary angiography in
Cangzhou central hospital from January 2007 to June
2010. For retrospective analysis, the subjects were
divided into non-CAD group (n = 860) and CAD group
(n = 589), which was then sub-grouped into pre-
menopausal CAD group (n = 167) and post-menopausal
CAD group (n = 422). The baseline characteristics of the
participants were recorded, including history of diabetes,
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hypertension, hyperlipidemia and myocardial infarction.
We also gathered information relevant to medications
and treatment strategies managed for the subjects, as
well as the results of coronary angiography. The partici-
pants were included into the CAD group when at least
one of their vascular lumens within left main (LM), left
anterior descending (LAD), left circumflex artery (LCX)
and right coronary artery (RCA) showed a diameter
stenosis of more than 50 %. Besides, patients satisfying
the following criterion would be excluded from our
study: (1) they have incomplete medical records; (2) they
simultaneously suffered from other myocardial disor-
ders, such as dilated cardiomyopathy and rheumatic
heart disease; (3) they concurrently have other severe
diseases related with liver, kidney, blood, tumor, endo-
crine, immunity system and so on; (4) they suffered from
amenorrhoea due to diverse causes or underwent estro-
gen replacement treatment (ERT); (5) they were diag-
nosed as psychosis; (6) they had history of operation or
trauma within 1 month. All participants have signed
informed consents, and the present study was approved
by the ethics committee of Cangzhou central hospital,
Hebei province.
Detection of biochemical indicators
Early next morning after hospitalization, fasting venous
food were drawn from patients, and fully automatic dry
biochemical analyzer (model: OLYMPUS-AU-5400) was
applied to detect certain biochemical indicators, includ-
ing levels of bilirubin, cholesterol, triglyceride, high-
density lipoprotein cholesterol (HDL-C) and low-density
lipoprotein cholesterol (LDL-C). Besides, blood routine
indicators, which mainly included leucocyte count,
neutrocyte proportion, red blood cell count and haemo-
globin level, were determined by blood analyzer (model:
LH 750), and fibrinogen levels were checked with coagu-
lation analyzer (model: ACL TOP).
Coronary arteriongraphy
Right radial artery or femoral artery was pierced with
Seldinger method, and they were projected with Judkin
method in multiple perspectives and multi-positions.
Left coronary artery was projected with ≥ 4 positions,
while right coronary artery was projected with ≥ 2 posi-
tions. The arteriography results were reviewed and
judged by experienced cardiologists and interventional
physicians. Based on the count of stenosed coronary
vessel, CAD lesions were categorized into single-vessel
lesions, double-vessel lesions and triple-vessel lesions.
Diagonal branch lesions were regarded as LAD, while
blunt circular lesions were deemed as LCX. Posterior
descending lesions and left ventricular lesions were
incorporated into RCA, and LM was calculated as a
single lesion. Moreover, considering the complexity of
the CAD lesions, they were classified as type A, type B
and type C in accordance with the guidelines of
American College of Cardiography (ACC)/American
Heart Association (AHA).
Genisin scoring
The degree of coronary artery stenosis was quantitatively
assessed by Genisin scoring: (1) 0 score when propor-
tion of stenosis = 0; (2) 1 score when proportion of
stenosis ≤ 25 %; (3) 2 scores when proportion of
stenosis achieved 26 % ~ 50 %; (3) 4 scores when pro-
portion of stenosis achieved 51 % ~ 75 %; (4) 8 scores
when proportion of stenosis achieved 76 % ~ 90 %; (5)
16 scores when proportion of stenosis achieved 91 %
~ 99 %; (6) 32 scores when proportion of stenosis
achieved 100 %. Different stenosis segments of coron-
ary arteries were based on Genisin scores multiplied
by corresponding coefficients: (1) x 5 for LM; (2) x 2.5 for
proximal ends of LCX and LAD; (3) x 1.5 for medium-
ends of LCX and LAD; (4) x 1 for far-ends of RCA/LAD/
LCX, first diagonal branch, second diagonal branch, pos-
terior descending branch, posterior collateral branch and
obtuse marginal branch. The stenosis score of coronary
arteries for each patient was the sum score of all branches.
Finally, five groups were drawn based on Genisin scores:
(1) group 1 (0 < sum ≤ 10); (2) group 2 (10 < sum ≤ 20); (3)
group 3 (20 < sum ≤ 34); (4) group 4 (34 < sum ≤ 64); (5)
group 5 (sum > 64).
Definition of risk indicators
The participants would be diagnosed with hypertension
if their systolic pressure was ≥ 140 mmHg and/or
diastolic pressure was ≥ 90 mmHg for three times in dif-
ferent days without taking anti-hypertensive drugs.
Diabetes was defined as the station that blood sugar
level was ≥ 11.1 mmol/L at any time, or fasting blood-
glucose (FDG) was ≥ 7.0 mmol/L, or blood sugar level
remained ≥ 11.1 mmol/L 2 h after loading [16]. The
diagnosis of hypertension accorded with the criteria that
the sitting blood pressure of participants were ≥ 130/85
mmHg. Smoking history was confirmed if subjects had
habits of regular smoking previously, or they smoked ≥ 1
cigarette/day for ≥ 1 year.
Detection of MAPK-1 levels with Strept Avidin-Biotin
Complex (SABC) method
Paraffin sections of samples were routinely placed in
xylene for transparent dewaxing and gradient alcohol for
hydration. After rinsing with distilled water for 3 times
(5 min for each time), the sections were immersed in 3 %
H2O2 at room temperature for 10 min to inactivate
endogenous enzymes. Then the sections were immersed
in 0.01 M citrate buffer solution (pH6.0) and simultan-
eously heated to boiling. When the boiled solution was
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cooled, it was cleansed with phosphate buffer saline (PBS)
(pH7.2-7.6) for 1–2 times. The bovine serum albumin
(BSA) sealing fluid was then dipped at room temperature
for 20 min. The primary antibody for p-MAPK (Stancruz
corporation, USA) was firstly dipped to incubate tissues at
37 °C for two hours, and then biotin goat-anti-mouse
secondary antibody was dipped at 37 °C for 20 min.
Subsequently, the reagent of SABC was dipped at the
temperature ranging from 20 to 37 °C for 20 min. Finally,
DAB color developing reagent kit was applied to color the
tissues, and hematoxylin was employed to redye the
tissues. The sections were observed under the micro-
scope and corresponding integrated optical density
(IOD) was processed with application of Image pro
plus software.
Evaluations of HIF-1 and HO-1 levels
The concentrations of HIF-1 and HO-1 in the serum
were detected with usage of ELISA detection kit (Shanghai
langdun biotech corporation, China). The sensitivities of
HIF-1 and HO-1 were 2 ng/L and 50 ng/L, respectively.
The experimental procedures were strictly in accord-
ance with the instructions of the kit. Specifically,
HIF-1 and HO-1 were added to the enzyme labeled
pores that were pre-packaged with antibodies of HIF-
1 and HO-1, and were then incubated. After cleans-
ing, HIF-1 and HO-1 antibodies that were marked
with horseradish peroxidase (HRP) were added, and
then substrates of A and B were supplemented to
generate blue, which was finally converted to yellow
under the influence of acid. The depth of colour was
positively correlated with concentrations of HIF-1
and HO-1 in samples.
Statistics
All the statistical analyses were conducted on the
basis of SPSS 18.0 software. Measurement data
(mean ± SD) were compared with student's t test,
while enumeration data in the form of percentages
(%) were compared with chi-square test. Data of
each group were examined to confirm whether they
conformed to normal distribution and homogeneity
of variance. Multi-group comparisons were con-
ducted with application of analysis of variance
(ANOVA). Correlation analysis was performed with
Pearson analysis. The regression model was established
to explore independent risk factors for premenopausal
and postmenopausal CAD. It was considered statistically
significant when P values were found to be less than 0.05.
Table 1 Comparison of baseline clinical characteristics among groups of non-CAD, premenopausal CAD and postmenopausal CAD
Indicators Non-CAD group Premenopausal-CAD group Postmenopausal-CAD group F/X2 P value
Size 860 167 422
BMI (kg/m2) 24.1 ± 2.4 24.3 ± 3.1 24.0 ± 2.1 1.0 0.36
Age (years old) 50.7 ± 2.7 50.8 ± 2.9 50.7 ± 1.2 2.4 0.09
Hypertension
yes 291 (33.8 %) 70 (41.9 %) 229 (54.3 %) 49.1 <0.05
no 569 (66.2 %) 97 (58.1 %) 193 (45.7 %)
Hyperlipoidemia
yes 204 (23.7 %) 37 (22.2 %) 141 (33.4 %) 15.4 <0.05
no 656 (76.3 %) 130 (77.8 %) 281 (66.6 %)
Diabetes
yes 108 (12.6 %) 29 (17.4 %) 124 (29.4 %) 54.3 <0.05
no 752 (87.4 %) 138 (82.6 %) 298 (70.6 %)
Family history
yes 140 (16.3 %) 64 (38.3 %) 75 (17.8 %) 44.6 <0.05
no 720 (83.7 %) 103 (61.7 %) 347 (82.2 %)
Smoking history
yes 151 (17.6 %) 55 (32.9 %) 96 (22.7 %) 21.4 <0.05
no 709 (82.4 %) 112 (67.1 %) 326 (77.3 %)
Obesity
yes 192 (22.3 %) 43 (25.7) 116 (27.5%) 4.4 0.11
no 668 (77.7 %) 124 (74.3 %) 306 (72.5 %)
Yan et al. Lipids in Health and Disease  (2016) 15:187 Page 4 of 11
Result
Baseline characteristics of subjects
Participants in non-CAD group, pre-menopausal CAD
group and post-menopausal CAD group were well
matched in terms of BMI and age without statistical
significance (P > 0.05) (Table 1). The occurrence of either
CAD or menopause seemed to be associated with
distinct incidences of hypertension, hyperlipoidemia,
diabetes (P < 0.05). Family history and smoking history
might also render development of CAD to be signifi-
cantly distinct (P < 0.05), yet the prevalence of obesity
was similar in this population (P > 0.05).
Comparison of coronary angiography indicators
Whether menopause occurred or not might not be asso-
ciated with the location of lesion vessels, since that no
significant difference was observed between the two
groups regarding lesion vessels within left main coronary
artery, anterior descending artery, circumflex coronary
artery and right coronary artery (P > 0.05) (Table 2).
However, post-menopause could be correlated with
larger proportions of double/triple vessel lesions and
higher degrees of lesion type (type A and type B) than
pre-menopause (P < 0.05).
Comparison of protein expressions relevant to MAPK
signaling pathway
Expressions of MAPK-1, HIF-1α and HO-1 in the pre-
menopausal group were found to over-number those in
the non-CAD group (P < 0.05), and the three proteins in
the post-menopausal group expressed even higher than
those in the pre-menopausal group (P < 0.05) (Table 3).
Additionally, significant correlations were found in the
non-CAD group, respectively, between HO-1 and HIF-1
(rs = 0.25, P < 0.05), p38MAPK and HIF-1 (rs = 0.20, P <
0.05), p38MAPK and HO-1 (rs = 0.12, P < 0.05) (Fig. 1).
Pre-menopausal group and post-menopausal group also
exhibited the similar tendencies of the three relations as
non-CAD group, which were specifically displayed as:
HO-1 and HIF-1(rs = 0.52, P < 0.05; rs = 0.34, P < 0.05),
p38MAPK and HIF-1 (rs = 0.28, P < 0.05; rs = 0.20, P <
0.05), p38MAPK and HO-1 (rs = 0.38, P < 0.05; rs = 0.23,
P < 0.05) (Figs. 2 and 3).
Comparison of CAD-related indicators
Among the thirteen indicators, the measured values of
around five parameters (i.e. SBP, CysC, hs-CRP, TG and
LDL-C) all conformed to the following tendency with
statistical significance: post-menopausal group > pre-
menopausal group > non-CAD group (P < 0.05) (Table 4).
Nonetheless, the remaining indicators were approximate
in their detection values among groups of non-CAD,
pre-menopausal CAD and post-menopausal CAD
(P > 0.05).
Among premenopausal women, MAPK-1 was indicated
to be positively correlated with TG (rs = 0.271, P < 0.001),
while HO-1 expressions increased with elevated CysC
(rs = 0.492, P < 0.001) and hs-CRP (rs = 0.569, P < 0.001)
Table 2 Comparison of coronary angiography indicators between groups of premenopausal CAD and postmenopausal CAD
Indicators Premenopausal-CAD group Postmenopausal-CAD group X2 P value
Lesion vessels
Left main coronary artery 6 (3.6 %) 18 (4.3 %) 1.1 0.78
Anterior descending artery 97 (58.1 %) 279 (66.1 %)
Circumflex coronary artery 92 (55.1 %) 269 (63.7 %)
Right coronary artery 72 (43.1 %) 246 (58.3 %)
Number of stenosed coronary vessel
Single vessel lesion 103 (61.7 %) 175 (41.5 %) 19.7 <0.05
Double vessel lesion 28 (16.8 %) 104 (24.6 %)
Triple vessel lesion 36 (21.5 %) 143 (33.9 %)
Lesion type
Type A 59 (35.3 %) 53 (12.6 %) 40.6 <0.05
Type B 71 (42.5 %) 230 (54.5 %)
Type C 37 (22.2 %) 139 (32.9 %)
Table 3 Comparison of protein expressions (MAPK-1, HIF-1α








MAPK-1a 3.5 ± 0.1 4.5 ± 0.1b 4.6 ± 0.1b,c
HIF-1α (ng/L) 9.4 ± 2.5 20.7 ± 6.1b 24.4 ± 7.6b,c
HO-1 (ng/L) 136.6 ± 52.8 382.1 ± 135.4b 413.7 ± 112.9b,c
aintegrated optical density (IOD) values
bcompared with non-CAD group
ccompared with pre-menopausal CAD group
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(Table 5). Slightly different from premenopausal popula-
tions, postmenopausal ones revealed positive associa-
tions of MAPK-1 with CysC (rs = 0.415, P < 0.001) and
TG (rs = 0.476, P < 0.001). The positive correlations
between HIF-1 and either hs-CRP (rs = 0.137, P =
0.005) or LDL-C (rs = 0.470, P < 0.001) could also be
found. Additionally, HO-1 exhibited positive linkages
with CysC (rs = 0.190, P < 0.001), hs-CRP (rs = 0.542,
P < 0.001) and TG (rs = 0.142, P = 0.004) as well.
Correlation between protein expressions relevant to
MAPK signaling pathway and coronary angiography
indicators
Interestingly, despite groups of non-CAD, pre-menopausal
CAD and post-menopausal CAD, expressions of HIF-1α
and HO-1 increased significantly with changes of lesion
vessels (left main coronary artery < anterior descend-
ing artery < circumflex coronary artery < right coronary
artery), number of stenosed coronary vessel (single
vessel lesion < double vessel lesion < triple vessel
lesion) and lesion type (type A < type B < type C)(P <
0.05) (Table 6). However, p38MAPK expressions
stayed stable irrespective of the place of lesion vessels
(P < 0.05), though its expressions also elevated with
rise in number of stenosed coronary vessel and lesion
type (P < 0.05).
Correlation between CAD-relevant indicators and Genesis
score
It was observed that merely SBP and TG appeared as in-
dependently hazardous factors for prediction of CAD
prognosis, with ORs of 1.02 (95 % CI = 1.01–1.18, P <
0.05) and 1.82 (95 % CI = 1.01–3.33, P < 0.05), respectively
(Table 7). Nevertheless, none of any other available associ-
ations were found between CAD-indicators and Genesis
score among both premenopausal and postmenopausal
populations (all P > 0.05).
Discussion
Among the classical factors, hypertension was demon-
strated to accelerate progression of atherosclerosis
through inducing continuous or repeated mechanical in-
juries of vascular endothelial cell layers [17]. Diabetes
was always accompanied by numerous metabolic disor-
ders, and it can even counteract the protective effects of
estrogen [18]. Moreover, the role of dyslipidemia, such
as high triglyceride (TG) in the plasm, in CAD develop-
ment also appeared to be crucial since that TG enabled
patients’ blood to be in a hypercoagulative state and
thereby elevated CAD risk [19]. C-reactive protein
(CRP) stimulated endothelial cells of aorta to generate
high levels of plasminogen activator inhibitor-1 (PAI-1),
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Fig. 2 Correlations among expressions of p38MAPK-1, HIF-1α and HO-1 in pre-menopausal CAD group
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plaques [20]. Increased heart rate (HR) reduced oxygen
supply and raised oxygen consumption, which spurred
production of arteriosclerosis and augmented incidence
of thrombus [21].
Besides, the onset of CAD seemed to be accompanied
with myocardial hypoxia [22], and inhibited p38MAPK
has been documented to worsen cellular injury under
exposure to hypoxia [23, 24]. In fact, p38MAPK could
be deemed as a candidate biomarker for CHD, owing to
the facts that it mediated development of cardiac failure
and that cardiac failure existed as a most severe disorder
of CHD [25]. It was also documented that suppression
of tumorigenicity 2 (ST2) could bind interleukin-33
(IL-33) on inflammatory membranes, thereby restrain-
ing and facilitating development of cardiovascular
disorders [26, 27]. The in vivo/in vitro experiments
conducted by Sanda et al. also demonstrated that
administration of IL-33 could serve to lower
p38MAPK expressions and Jun N-terminal kinase
phosphorylation aroused by angiotensin II, which
caused cardiac dysfunctions through generation of
certain reactive oxygen species (ROS) [28]. All in all,
the effects of p38MAPK on cardiovascular functions
appeared to be regulated by ST2/IL-33 signaling,
though the inherent pathogenesis needed to be fur-
ther identified.
In addition, p38MAPK also remarkably up-regulated
HIF-1α expressions in the hypoxic myocardium [29, 30].
The elevated HIF-1α expressions in acute ischemic
myocardial tissue facilitated increase of capillary density
within the damaged myocardium areas [31], where
micro-circulation was effectively constructed [32]. Accu-
mulating evidence also confirmed that the hypoxic pre--
conditioning (HPC) mechanism mobilized by activated
HIF-1α not only eased arrhythmia after ischemia-
reperfusion via improving intracellular ion disorder, but
also ameliorated blood supply by way of releasing
endothelium-derived relaxing factor (EDRF) [33, 34].
Moreover, restrained HIF-1α expressions could antagonize
the formation of new blood cells by repressing VEGF ex-
pressions, accordingly alleviating the incidence of in-stent
restenosis when inhibitors of HIF-1α (e.g. mTOR and pac-
litaxel) were painted on the bracket [35].
As an endogenous protective factor, HO-1 was subject
to regulation of HIF-1α [36]. Under the stimulation of
ischemia and hypoxia, HO-1 functioned to resist athero-
sclerosis, ischemia repercussion injury and myocardial
hypertrophy mainly through catalysing degradation of
haem into bilirubin, CO and ferroprotein [37, 38].
Bilirubin has been documented to be associated with
less susceptibility to CHD for its crucial roles in in-
hibition of lipid oxidation, clearance of ohyradicals and
suppression of complement response during inflammation
development [39–41]. In addition, CO could potentially
block the inflammatory process through depressing gener-
ation of inflammatory factors that were relevant to NO
and cGMP, whereas ferroprotein prevented cells from










































Fig. 3 Correlations among expressions of p38MAPK-1, HIF-1α and HO-1 in post-menopausal CAD group
Table 4 Comparison of CAD-related indicators among groups







SBP (mm Hg) 123.0 ± 14.7 134.9 ± 16.3a 140.5 ± 18.1a,b
DBP (mm Hg) 80.5 ± 9.2 83.8 ± 10.5 82.6 ± 9.7
Heart rate (/min) 86 ± 10 88 ± 17 88 ± 14
FBG (mmol/L) 7.6 ± 1.5 9.3 ± 0.8 10.4 ± 1.3
2 h PG (mmol/L) 12.3 ± 1.9 15.2 ± 2.3 15.9 ± 2.1
BUN (mmol/L) 6.9 ± 1.6 7.7 ± 2.7 8.2 ± 3.5
Cr (μmol/L) 76.7 ± 16.5 84.1 ± 24.1 88.8 ± 21.9
CysC (mg/dL) 1.1 ± 0.2 1.4 ± 0.3a 1.8 ± 0.2a,b
hs-CRP (mg/L) 0.7 ± 0.2 12.8 ± 8.3a 16.5 ± 7.9a,b
TC (mmol/L) 4.4 ± 0.7 4.7 ± 1.1 4.6 ± 0.8
TG (mmol/L) 1.7 ± 0.1 1.8 ± 0.7a 2.1 ± 0.6a,b
HDL-C (mmol/L) 1.4 ± 0.3 1.2 ± 0.1 1.4 ± 0.3
LDL-C (mmol/L) 2.4 ± 0.9 3.2 ± 0.6a 3.9 ± 0.7a,b
acompared with non-CAD group
bcompared with pre-menopausal CAD group
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In addition, postmenopause made female CAD pa-
tients more susceptible to hazard factors of cardiovascu-
lar diseases owing to shortage of estrogen. Estrogen not
merely regulated blood lipid levels and reduced the
chance of atherosclerosis, but also ameliorated a series
of vascular endothelial functions, which were specifically
indicated as dilation of coronary vessels, increase of
coronary flow and reduction of coronary artery spasm.
Furthermore, estrogen also inhibited migration of
monocytes to subendothelial, and thereby restrained their
transformation to foam cells after swallowing lipids [44].
Estrogen was also advantageous in restraining prolifera-
tion of vascular smooth muscle cells and antagonizing
aggregation of platelets. In spite of the above merits, estro-
gen could aggravate premenopausal CAD when diabetes
was combined, which might be explained by that estrogen
can stimulate RAGE expressions within endothelial cells
and potentiate advanced glycation end products (AGE)-
Table 5 Correlations between protein expressions (MAPK-1,HIF-1α and HO-1) and CAD-related indicators among groups of premen-
opausal and postmenopausal women
Indicators Premenopausal-CAD group Postmenopausal-CAD group
MAPK-1 HIF-1α HO-1 MAPK-1 HIF-1α HO-1
BMI (kg/m2) −0.07 (0.39) −0.02 (0.83) 0.05 (0.55) −0.06 (0.23) −0.02 (0.74) −0.01 (0.84)
SBP (mm Hg) −0.01 (0.93) 0.08 (0.32) −0.09 (0.26) 0.05 (0.36) −0.01 (0.83) 0.08 (0.12)
DBP (mm Hg) 0.11 (0.15) 0.02 (0.78) 0.09 (0.23) −0.05 (0.3) −0.02 (0.63) 0.07 (0.15)
Heart rate (/min) −0.04 (0.59) 0.04 (0.65) 0.01 (0.91) 0.02 (0.66) 0.01 (0.88) −0.06 (0.26)
FBG (mmol/L) 0.06 (0.41) 0.09 (0.23) −0.1 (0.22) 0.01 (0.81) 0.04 (0.42) 0.04 (0.42)
2 h PG (mmol/L) 0.14 (0.08) −0.06 (0.43) −0.03 (0.7) 0.08 (0.1) −0.01 (0.78) 0.02 (0.72)
BUN (mmol/L) −0.13 (0.09) 0.04 (0.62) 0.06 (0.42) −0.03 (0.59) 0.06 (0.24) −0.01 (0.78)
Cr (μmol/L) 0.06 (0.43) 0.02 (0.78) 0.04 (0.65) 0.05 (0.35) −0.01 (0.93) 0.00 (0.95)
CysC (mg/dL) 0.08 (0.31) 0.05 (0.52) 0.49 (<0.05) 0.42 (<0.05) 0.00 (0.98) 0.19 (<0.05)
hs-CRP (mg/L) 0.08 (0.29) 0.03 (0.75) 0.57 (<0.05) 0.08 (0.11) 0.14 (0.01) 0.54 (<0.05)
TC (mmol/L) −0.15 (0.05) 0.08 (0.31) 0.01 (0.88) 0.01 (0.91) 0.00 (0.99) 0.06 (0.24)
TG (mmol/L) 0.27 (<0.05) 0.06 (0.43) 0.03 (0.72) 0.48 (<0.05) 0.04 (0.45) 0.14 (<0.05)
HDL-C (mmol/L) 0.01 (0.87) 0.07 (0.39) −0.12 (0.13) −0.02 (0.72) 0.01 (0.82) 0.03 (0.53)
LDL-C (mmol/L) −0.15 (0.05) 0.08 (0.32) −0.08 (0.33) 0.01 (0.92) 0.47 (<0.05) 0.01 (0.88)
*The results were presented as rs and P value
Table 6 Correlations between protein expressions (MAPK-1,HIF-1αand HO-1) and coronary angiography indicators among groups of
premenopausal and postmenopausal women
Indicators Premenopausal-CAD group Postmenopausal-CAD group
MAPK-1 HIF-1α (ng/L) HO-1 (ng/L) MAPK-1 HIF-1α (ng/L) HO-1 (ng/L)
Lesion vessels
Left main coronary artery 4.4 ± 0.1 13.8 ± 4.3 230.5 ± 50.2 4.7 ± 0.2 15.8 ± 4.2 264.3 ± 89.8
Anterior descending artery 4.5 ± 0.1 17.2 ± 7.3* 374.4 ± 195.3* 4.7 ± 0.12 21.4 ± 10.1* 397.7 ± 159.4*
Circumflex coronary artery 4.5 ± 0.1 20.3 ± 11.3@ 419.6 ± 210.1@ 4.8 ± 0.1 29.9 ± 12.1@ 482.8 ± 278.4@
Right coronary artery 4.6 ± 0.2 24.1 ± 14.2& 527.1 ± 273.1& 4.8 ± 0.1 35.9 ± 15.0& 598.1 ± 262.1&
Number of stenosed coronary vessel
Single vessel lesion 4.5 ± 0.2 16.0 ± 3.5 283.6 ± 82.0 4.7 ± 0.2 16.1 ± 3.7 278.4 ± 91.7
Double vessel lesion 4.5 ± 0.1a 19.3 ± 9.9a 409.7 ± 175.3a 4.7 ± 0.1a 23.6 ± 10.1a 349.8 ± 183.2a
Triple vessel lesion 4.5 ± 0.2b 29.1 ± 13.2b 561.6 ± 280.6b 4.8 ± 0.1b 39.6 ± 13.2b 637.9 ± 257.6b
Lesion type
Type A 4.4 ± 0.2 14.7 ± 2.9 236.9 ± 90.2 4.7 ± 0.1 18.7 ± 4.5 293.5 ± 85.4
Type B 4.5 ± 0.1c 17.6 ± 8.1c 418.7 ± 161.3c 4.7 ± 0.1c 25.1 ± 7.9c 375.8 ± 155.5c
Type C 4.6 ± 0.2d 30.7 ± 11.4d 520.6 ± 224.5d 4.8 ± 0.2d 34.7 ± 10.8d 614.5 ± 249.5d
*: compared with left main coronary artery; @: compared with anterior descending artery; &: compared with circumflex coronary artery; a: compared with single
vessel lesion; b: compared with double vessel; c: compared with type A; d: compared with type B
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RAGE interactions, finally exacerbating vascular inflam-
mation [45].
Intriguingly, estrogen was also suggested to modulate
p38 MAPK activity and HO-1 expressions [46]. Particu-
larly, administration of 17 beta-estradiol (E(2)) for trauma-
hemorrhage patients would normalized p38 MAPK, yet
not HO-1 expressions, whereas addition of p38MAPK in-
hibitor abolished the increase of HO-1 expressions due to
trauma haemorrhage [46]. It was also indicated that MAPK
may phosphorylate certain targets (e.g. p27) that resulted
in anti-estrogen resistance [47]. For another, E2 imposed
effects primarily through binding to the estrogen receptors
(ERα and ERbelta) or interacting with elements related
with estrogen response [48]. Lower ERα expressions were
determined in HIF-1α positive breast cancers than in HIF-
1α ones [49]. Simultaneously, down-regulated ERα and
inhibited influence of anti-estrogen could also be observed
in the oxygen-lacking state [50], suggesting the inter-
correlation between hypoxia, ERα and HIF-1α.
Conclusions
Thus, it was reasonable to consider that p38MAPK-1/
HIF-1α/HO-1 were highly associated with coronary le-
sion characteristics and prognosis for peri-menopausal
women, providing clues that p38MAPK-1/HIF-1α/HO-1
could act as biomarkers for diagnosis and prognosis of
peri-menopausal women suffering from CAD.
Abbreviations
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